PMID: 8605280Jan 1, 1996Paper

Autoimmune hemolytic anemia in patients with de novo acute myelocytic leukemia

Annals of Hematology
H TamuraT Nomura

Abstract

Autoantibody against erythrocytes has occasionally been observed in patients with de novo acute myelocytic leukemia (AML). However, it is not clear whether this autoantibody in AML patients induces frank hemolysis (autoimmune hemolytic anemia, AIHA), as seen in lymphoid neoplasms. We present two de novo AML patients who showed hemolysis due to antiglobulin test-positive and test-negative AIHA, respectively. AIHA should be considered as one cause of anemia in de novo AML patients, and blood transfusions should be given carefully in such cases to avoid harmful hemolysis.

References

Feb 1, 1990·The American Journal of Medicine·Y M Arbaje, G Beltran
Oct 1, 1989·Journal of Clinical Pathology·R J SokolD J Booker
Jan 1, 1969·Progress in Hematology·J V Dacie, S M Worlledge
Jan 1, 1984·Clinical and Laboratory Haematology·A K Mangal, N A Buskard
Aug 1, 1984·British Journal of Haematology·P Solal-CelignyP Boivin
Sep 1, 1993·Annals of Hematology·B HertensteinH Heimpel
Feb 1, 1955·A.M.A. Archives of Internal Medicine·A M FRUMIN, A KOHN

❮ Previous
Next ❯

Citations

Jul 14, 2005·Journal of Pediatric Hematology/oncology·David T Teachey, Carolyn A Felix
Jul 16, 2005·Pediatric Hematology and Oncology·Lale Olcay, Ahmet Koç
Jan 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Armin Zebisch, Heinz Sill
Feb 27, 2021·SAGE Open Medical Case Reports·Dmitri PchejetskiKyaw Maw

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Autoimmune Hemolytic Anemia

Autoimmune hemolytic anemia (AIHA) occurs when antibodies directed against the person's own red blood cells (RBCs) cause them to burst (lyse), leading to an insufficient number of oxygen-carrying red blood cells in the circulation. Discover the latest research on AIHA here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.